Navigation Links
Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
Date:6/18/2009

ward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
2. Novavax Reports First Quarter 2009 Financial Results
3. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
4. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
5. Novavax Announces Early Retirement of $17 Million of Convertible Debt
6. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
9. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
11. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a ... manufacture and sale of enzyme and protein products ... today announced financial results for the quarter ended ... this press release should be read in conjunction ...
... SynCo Bio Partners B.V., one of the leading GMP contract ... is again fully operational and SynCo has produced and released ... expansion of its Class A zone.   The ... in SynCo,s strategy in supporting its clients with new product ...
... for gram, novel carbon nanofiber-filled coatings devised by researchers ... and Texas A&M University outperformed conventional flame retardants used ... by at least 160 percent and perhaps by as ... reported in the journal Polymer ,* suggest that ...
Cached Biology Technology:Dyadic International Reports 2011 Second Quarter Financial Results 2Dyadic International Reports 2011 Second Quarter Financial Results 3Dyadic International Reports 2011 Second Quarter Financial Results 4Dyadic International Reports 2011 Second Quarter Financial Results 5Dyadic International Reports 2011 Second Quarter Financial Results 6Dyadic International Reports 2011 Second Quarter Financial Results 7SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:4/15/2014)... 2014, Irvine, Calif. UC Irvine neurobiologists have found ... when transplanted into the brains of mice with the ... is published in the journal Stem Cells Research ... to work in two different mouse models. , ... dementia, is associated with accumulation of the protein amyloid-beta ...
(Date:4/15/2014)... know as early as 2020 how high sea levels ... team of researchers including Florida International University scientist Rene ... Science Foundation,s (NSF) Florida Coastal Everglades Long-Term Ecological Research ... in ecosystems from coral reefs to deserts, mountains to ... sea level rise is one of the most certain ...
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
Breaking Biology News(10 mins):UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Long-term predictions for Miami sea level rise could be available relatively soon 2Biologists develop nanosensors to visualize movements and distribution of plant hormone 2
... insect brains, mouth bacteria behaving badly and the hundreds ... just some of the highlights at the Society for ... The annual event takes place on 6-9 September at ... international experts will present cutting-edge scientific research covering a ...
... Carolina State University shows that a species of shellfish widely ... actually increased in size, despite and possibly because of ... found indicates that human activity does not necessarily mean that ... species even a species that people relied on as ...
... filter-feeder, that anchors itself to the sea bed, offers new ... Ice Sheet a region that is thought to be ... for the Census of Antarctic Marine Life (CAML), scientists from ... coastal and deep sea regions around the continent and from ...
Cached Biology News:Archaeological study shows human activity may have boosted shellfish size 2Marine animals suggest evidence for a trans-Antarctic seaway 2
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Leucine-rich repeat-containing G-protein coupled receptor 4...
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
Biology Products: